First clinical study that will apply the immunizer to 90 volunteers aged between 18 and 55 years old
Property security technician Wenderson Nascimento Souza, 34 years old, was the first to receive the dose of the Brazilian vaccine, at the beginning of the clinical study that will apply the immunizer to 90 volunteers aged between 18 and 55 years old. The application was made today by the Secretary of Research and Scientific Training of the Ministry of Science, Technology and Innovations (Sepef/MCTI), Marcelo Morales.
“We are now going to measure the specific immune response and assess the cellular immunity of the participants,” explained infectious disease specialist Roberto Badaró, responsible for research and development of the vaccine, in a ceremony held at the headquarters of the National Service for Industrial Learning (Senai), in Salvador. .
The researcher’s expectation is that the first phase of the study will be completed in three months, and that, if all goes well, in a year or so the vaccine will be available.
Vaccine – The RNA MCTI CIMATEC HDT immunizer is composed of two parts, which are mixed before application: an RNA replicon molecule (repRNA) and an emulsion composed of water and a special type of oil and magnetic molecules, called Lion, which helps protect the repRNA molecule and transports it to target cells.
According to infectious disease specialist Roberto Badaró, the Brazilian vaccine, which is of the third generation, has some specific benefits, such as the use of a smaller number of components, and can be applied in lower doses and without the need for consecutive immunizations. “We may, in a sequence and with the ability to synthesize the five variants in a single protein, have a vaccine with the five variants in the future. Therefore, we can have the vaccine that will be routinely used”, explained the infectious disease doctor.
The pre-clinical and clinical development of the vaccine has the participation of the United States, Brazil and India, through a partnership between the HDT BioCorp companies. (United States), Senai Cimatec (Brazil) and Gennova Biopharmaceuticals (India). In Brazil, the partnership is supported by RedeVírus and financed by the MCTI.